CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled
Drug / intervention
Dermaprazole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04865731
NCT04865731Phase 2Completed
CompareCT.gov

A Phase II Clinical Trial of Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer Patients (CTMS# 20-0147)

The University of Texas Health Science Center at San Antonio·interventional·Posted Apr 29, 2021·Updated Aug 6, 2025

In Brief

A Phase 2 clinical trial evaluating Dermaprazole and Aquaphor for Cancer of the Head and Neck. Completed, enrolled 6 participants across 1 site.

Detailed Summary

In this study, the study team seek to conduct a pilot clinical study to evaluate the safety and efficacy of a reformulated proton pump inhibitor (PPI) cream (Dermaprazole) in definitive head and neck cancer (HNC) patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer of the Head and Neck
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedApr 29, 2021
Enrollment StartJun 15, 2022
Primary CompletionJun 18, 2024
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.2 years ago

Interventions

Dermaprazoledrug

Patients will be managed with twice daily prophylactic use of the proposed intervention (Dermaprazole) topical cream for radiation dermatitis. The amount of cream will be 2cc per application and will be measured in pre-filled capped syringes for every application.

Aquaphordrug

Patients will be managed with twice daily prophylactic use of Aquaphor. The amount of Aquaphor will be 2cc per application and will be measured in pre-filled capped syringes for every application.